GLP3.io

Why this name

The .io ending reads as engineering: dashboards, APIs, models, pipelines. Set against a metabolic-peptide shorthand, it describes a company that computes rather than compounds — discovery software, patient monitoring, adherence tracking, real-world evidence analysis. Investors and technical hires parse that combination instantly.

Suited to a computational drug discovery startup working on peptide design, a digital health platform supporting patients on metabolic therapy, or a data company aggregating outcomes for payers and clinics. A biology-heavy descriptive name would recruit the wrong candidates and confuse the pitch; this one tells a developer and a physician different but compatible things, which is precisely the audience a health-tech company has to address at once.

Well suited to

• Computational peptide design platform
• Digital health app for metabolic therapy patients
• Real-world evidence and outcomes analytics
• Clinic-facing adherence and monitoring dashboard

Ideal owner A health-tech or computational biology startup working in the metabolic therapy space.